drugset
Drugs / SONALA-001
last change Jul 2024 re-read 3 minutes ago

SONALA-001

also known as ALA
Developed for
glioblastoma
Investigated by
SonALAsense, Inc.

Trials 1

today NCT05370508 · Ph 1/2
2023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT05370508 Feb 2023 → Jun 2024 glioblastoma SonALAsense, Inc. Terminated No outcome recorded Stop: Business

Press releases naming this drug 2 releases

DateIssuerRelease
2023-11-14 SonALAsense, Inc. FDA Grants Fast Track Designation to SonALAsense’s SONALA-001 in Combination with the INSIGHTEC Transcranial Ultrasound Device for Sonodynamic Therapy of DIPG, a Rare Pediatric Brain Cancer sonalasense.com ↗
2023-03-08 SonALAsense, Inc. SonALAsense Announces Completion of First Cohort in Phase 2 Study of SONALA-001 Sonodynamic Therapy for Recurrent Glioblastoma sonalasense.com ↗

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as SONALA-001 “10 mg/kg IV SONALA-001 (ALA) and MR-guided Focused Ultrasound (MRgFUS)” NCT05370508 ↗
Known as ALA ClinicalTrials.gov intervention name — accepted as the source's own label NCT05370508 ↗
Route Intravenous “10 mg/kg IV SONALA-001 (ALA)” NCT05370508 ↗